Integrated BioPharma’s QQ1 2026 quarter delivered a modest net income of $0.123 million on positive operating cash flow of $1.301 million and free cash flow of $1.128 million. Gross profit stood at $1.019 million against selling, general and administrative expenses of $0.856 million, yielding operating income of $0.163 million and pre-tax income of $0.196 million. Net income translated to an EPS of $0.004 (diluted $0.0039) with 31.06 million weighted-average shares outstanding. Cash burn on investments remained modest (capital expenditures of $0.173 million), supporting a net cash inflow of approximately $1.118 million for the period and an ending cash balance of $4.732 million.
From a liquidity standpoint, the balance sheet shows solid near-term liquidity: total current assets of $19.624 million against current liabilities of $4.764 million, and a net cash position (net debt of roughly -$3.971 million) driven by cash of $4.732 million and limited outstanding debt ($0.761 million total). Yet, the company carries a substantial accumulated deficit reflected in retained earnings of -$31.296 million, underscoring a long-running profitability challenge even as cash flow supports near-term operating flexibility.
Revenue visibility remains constrained in the disclosed QQ1 2026 data (revenue for Q1 2026 is not provided in the dataset). The company’s quarterly gross margin declined year-over-year and quarter-over-quarter by 20.64% and 34.30% respectively, indicating margin pressure, while operating income and net income declined meaningfully on a YoY and QoQ basis. Absent an explicit revenue line for QQ1 2026, the quarterly bottom-line improvement appears to be driven by cost discipline and favorable non-operating items rather than top-line growth. Management commentary from the earnings call is not in the provided data, limiting the ability to quote specific strategic remarks.